Form 4: Kyverna Therapeutics CEO Warner Weston Biddle Reports Stock Option Grant
SEC Form 4
Kyverna Therapeutics CEO Warner Weston Biddle reports the acquisition of stock options.
Summary
- Warner Weston Biddle, CEO of Kyverna Therapeutics, filed a Form 4 on April 15, 2025, reporting a transaction.
- The transaction involved the acquisition of stock options, specifically a right to buy 332,500 shares of common stock at an exercise price of $2.06.
- The options were granted on April 11, 2024, and expire on April 11, 2035.
- The vesting schedule for the options is as follows: 1/4th vests on April 11, 2026, and 1/48th vests monthly thereafter, contingent upon continuous service to Kyverna Therapeutics.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The grant of stock options is a standard practice and aligns management with shareholder interests. The vesting schedule promotes long-term commitment.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- The size of the grant (332,500 shares) and the vesting schedule (1/4th on April 11, 2026, and 1/48th monthly thereafter) are typical for a CEO of a company at Kyverna's stage.
- Comparable companies like Arcellx and Cabaletta Bio also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 04/11/2024 | Date of stock option grant |
| 04/11/2025 | Date of earliest transaction |
| 04/15/2025 | Form 4 filing date |
| 04/11/2026 | Initial vesting date for 1/4th of the shares |
| 04/11/2035 | Expiration date of the stock options |
Keywords
Form 4, stock options, Kyverna Therapeutics, KYTX, CEO, Warner Weston Biddle, beneficial ownership, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.